Despite Katie Couric’s Advice, Doctors Say Ultrasound Breast Exams May Not Be Needed

Image
usf health primary care :: Article Creator The VA Adds A Veterans Health Clinic In An East Tampa Neighborhood A new satellite clinic run by the Department of Veteran Affairs in East Tampa is open for veterans to get primary care, mental health support and other services. It's part of a growing partnership between the Department of Veterans Affairs and Department of Defense. Officials from both agencies celebrated the Sabal Park clinic's grand opening during a ceremony on Monday. In the last year, the VA reported nearly 33,000 veterans in Florida signed up for health care. Many of them live in the Tampa Bay region, which has one of the largest veteran populations in the U.S. "It is always a challenge to have capacity meet that ever-growing demand, but it is our obligation to catch up to that demand as much as possible," Dr. Shereef Elnahal, VA Under Secretary for Health, said at the event. Stephanie Colombini / WUS

€7.34m for cancer vaccine developer - European Biotechnology

Having secured a €2.785m grant from the EU and €4.55m from a Series B round, MaxiVAX is going full steam ahead with its Phase II cancer vaccine programmes.

Private clinical-stage biotech MaxiVAX announced that it has been awarded a European Commission grant of €2,785,000, thanks to the Horizon 2020 EIC Accelerator Programme. In addition, the company successfully closed a Series B2 round of CHF5m (€4.55m). Founded by the father and son team Bernard and Nicholas Mach, the Geneva-based biotech is focused on developing personalized anti-cancer vaccination.

MaxiVAX will use the funds to support the clinical development programmes which include the multi-centric efficacy Phase II trial for advanced, refractory head and neck cancers that is currently ongoing in Switzerland. The company will also start preparations for an international Phase II clinical study in a yet to be disclosed rare cancer indication, for which the FDA accepted the Investigational New Drug application in July 2018. The new funds will also be used to scale up production of the company’s lead compound, MVX-ONCO-1. MVX-ONCO-1 is the first personalised cell-based cancer immunotherapy using encapsulation cell technology. Therapy is individualised and can be applied to any cancer type.

“This important and welcome funding now enables us to move forward and accelerate our clinical programmes in Switzerland, Europe and the US,” commented MaxiVAX CEo Dimitrios Goundis. “We are encouraged by the progress in our ongoing Head & Neck Phase 2 trial, and look forward to its completion in 2021.”



https://ift.tt/35AF20S

Comments

Popular posts from this blog

Observership Program listings for international medical graduates

Vaccination Sites | Covid-19

Vaccination Sites | Covid-19